These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 9505989)

  • 1. Olanzapine: interaction study with imipramine.
    Callaghan JT; Cerimele BJ; Kassahun KJ; Nyhart EH; Hoyes-Beehler PJ; Kondraske GV
    J Clin Pharmacol; 1997 Oct; 37(10):971-8. PubMed ID: 9505989
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Olanzapine. Pharmacokinetic and pharmacodynamic profile.
    Callaghan JT; Bergstrom RF; Ptak LR; Beasley CM
    Clin Pharmacokinet; 1999 Sep; 37(3):177-93. PubMed ID: 10511917
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The in vivo effects of olanzapine and other antipsychotic agents on receptor occupancy and antagonism of dopamine D1, D2, D3, 5HT2A and muscarinic receptors.
    Zhang W; Bymaster FP
    Psychopharmacology (Berl); 1999 Jan; 141(3):267-78. PubMed ID: 10027508
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lack of effect of olanzapine on the pharmacokinetics of a single aminophylline dose in healthy men.
    Macias WL; Bergstrom RF; Cerimele BJ; Kassahun K; Tatum DE; Callaghan JT
    Pharmacotherapy; 1998; 18(6):1237-48. PubMed ID: 9855322
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of fluoxetine on olanzapine pharmacokinetics.
    Gossen D; de Suray JM; Vandenhende F; Onkelinx C; Gangji D
    AAPS PharmSci; 2002; 4(2):E11. PubMed ID: 12102620
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Olanzapine: pharmacology, pharmacokinetics and therapeutic drug monitoring].
    Rao ML; Hiemke C; Grasmäder K; Baumann P;
    Fortschr Neurol Psychiatr; 2001 Nov; 69(11):510-7. PubMed ID: 11704898
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of antipsychotic drug treatment on prolactin concentrations in elderly patients.
    Kinon BJ; Stauffer VL; McGuire HC; Kaiser CJ; Dickson RA; Kennedy JS
    J Am Med Dir Assoc; 2003; 4(4):189-94. PubMed ID: 12837139
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A pharmacokinetic interaction between carbamazepine and olanzapine: observations on possible mechanism.
    Lucas RA; Gilfillan DJ; Bergstrom RF
    Eur J Clin Pharmacol; 1998 Oct; 54(8):639-43. PubMed ID: 9860152
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of probenecid on the disposition of risperidone and olanzapine in healthy volunteers.
    Markowitz JS; Devane CL; Liston HL; Boulton DW; Risch SC
    Clin Pharmacol Ther; 2002 Jan; 71(1):30-8. PubMed ID: 11823755
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of ritonavir on olanzapine pharmacokinetics in healthy volunteers.
    Penzak SR; Hon YY; Lawhorn WD; Shirley KL; Spratlin V; Jann MW
    J Clin Psychopharmacol; 2002 Aug; 22(4):366-70. PubMed ID: 12172335
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypotension and bradycardia in a healthy volunteer following a single 5 mg dose of olanzapine.
    Markowitz JS; DeVane CL; Boulton DW; Liston HL; Risch SC
    J Clin Pharmacol; 2002 Jan; 42(1):104-6. PubMed ID: 11808820
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Olanzapine: a novel atypical neuroleptic agent.
    Reus VI
    Lancet; 1997 May; 349(9061):1264-5. PubMed ID: 9142055
    [No Abstract]   [Full Text] [Related]  

  • 13. Interaction between olanzapine and haloperidol.
    Gomberg RF
    J Clin Psychopharmacol; 1999 Jun; 19(3):272-3. PubMed ID: 10350035
    [No Abstract]   [Full Text] [Related]  

  • 14. Striatal and temporal cortical D2/D3 receptor occupancy by olanzapine and sertindole in vivo: a [123I]epidepride single photon emission tomography (SPET) study.
    Bigliani V; Mulligan RS; Acton PD; Ohlsen RI; Pike VW; Ell PJ; Gacinovic S; Kerwin RW; Pilowsky LS
    Psychopharmacology (Berl); 2000 Jun; 150(2):132-40. PubMed ID: 10907666
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro and in vivo biochemistry of olanzapine: a novel, atypical antipsychotic drug.
    Bymaster FP; Rasmussen K; Calligaro DO; Nelson DL; DeLapp NW; Wong DT; Moore NA
    J Clin Psychiatry; 1997; 58 Suppl 10():28-36. PubMed ID: 9265914
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of ethinylestradiol-containing contraceptives on the serum concentration of olanzapine and N-desmethyl olanzapine.
    Haslemo T; Refsum H; Molden E
    Br J Clin Pharmacol; 2011 Apr; 71(4):611-5. PubMed ID: 21395655
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Double-blind olanzapine vs. haloperidol D2 dopamine receptor blockade in schizophrenic patients: a baseline-endpoint.
    Bernardo M; Parellada E; Lomeña F; Catafau AM; Font M; Gómez JC; López-Carrero C; Gutiérrez F; Pavía J; Salamero M
    Psychiatry Res; 2001 Aug; 107(2):87-97. PubMed ID: 11530275
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multilead quantitative electroencephalogram profile and cognitive evoked potentials (P300) in healthy subjects after a single dose of olanzapine.
    Hubl D; Kleinlogel H; Frölich L; Weinandi T; Maurer K; Holstein W; Czekalla J; Dierks T
    Psychopharmacology (Berl); 2001 Nov; 158(3):281-8. PubMed ID: 11713618
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Behavioral pharmacology of olanzapine: a novel antipsychotic drug.
    Moore NA; Leander JD; Benvenga MJ; Gleason SD; Shannon H
    J Clin Psychiatry; 1997; 58 Suppl 10():37-44. PubMed ID: 9265915
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dosing the antipsychotic medication olanzapine.
    Nemeroff CB
    J Clin Psychiatry; 1997; 58 Suppl 10():45-9. PubMed ID: 9265916
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.